Bladder cancer incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of bladder cancer, 2015-2017, UK.

 

Proportion of all cases

Percentage bladder cancer is of total cancer cases, 2015-2017, UK.

 

Age

Peak rate of bladder cancer cases, 2015-2017, UK

Trend over time

Change in bladder cancer incidence rates since the early 1990s, UK

 

Bladder cancer is the 11th most common cancer in the UK, accounting for 3% of all new cancer cases (2017).[1-4]

In females in the UK, bladder cancer is the 16th most common cancer (2% of all new female cancer cases). In males in the UK, it is the 8th most common cancer (4% of all new male cancer cases).

27% of bladder cancer cases in the UK are in females, and 73% are in males.

Bladder cancer incidence rates (European age-standardised (AS) rates) Open a glossary item for persons are significantly lower than the UK average in Wales, and similar to the UK average in all other UK constituent countries.

Bladder Cancer (C67), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 2,359 255 128 63 2,805
Crude Rate 8.4 9.2 8.1 6.6 8.4
AS Rate 8.2 8.7 7.2 7.0 8.2
AS Rate - 95% LCL 7.9 7.6 6.0 5.3 7.9
AS Rate - 95% UCL 8.5 9.7 8.5 8.7 8.5
Male Cases 6,327 580 353 168 7,428
Crude Rate 23.0 22.0 22.9 18.3 22.8
AS Rate 27.6 25.6 24.3 24.1 27.2
AS Rate - 95% LCL 26.9 23.5 21.7 20.5 26.6
AS Rate - 95% UCL 28.3 27.7 26.8 27.8 27.8
Persons Cases 8,686 835 481 231 10,233
Crude Rate 15.6 15.4 15.4 12.3 15.5
AS Rate 16.8 16.1 14.8 14.5 16.6
AS Rate - 95% LCL 16.5 15.0 13.5 12.6 16.3
AS Rate - 95% UCL 17.2 17.1 16.2 16.4 16.9

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item
 

For bladder cancer, like most cancer types, differences between countries largely reflect risk factor prevalence in years past.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C67.

Last reviewed:

Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2015-2017, on average each year almost 6 in 10 new cases (56%) were in people aged 75 and over.[1-4]

Age-specific incidence rates rise gradually from around age 50-54 in both males and females, with a sharper rise in males from age 60-64.The highest rates are in in the 90+ age group for females and males.

Incidence rates are significantly lower in females than males in a number of (mainly older) age groups.The gap is widest at age 75 to 79, when the age-specific incidence rate is 3.5 times lower in females than males.

Bladder cancer (C67), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For bladder cancer, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, C21.

Last reviewed:

Bladder cancer European age-standardised (AS) Open a glossary item incidence rates for females and males combined decreased by 42% in the UK between 1993-1995 and 2015-2017.[1-4] The decrease was larger in males than females.

For females, bladder cancer AS incidence rates in the UK decreased by 40% between 1993-1995 and 2015-2017. For males, bladder cancer AS incidence rates in the UK decreased by 46% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), bladder cancer AS incidence rates for females and males combined decreased by 16%.[1-4] In females AS incidence rates decreased by 15%, and in males rates decreased by 19%.

Bladder Cancer (ICD-10 C67), European Age-Standardised Incidence Rates, UK, 1993-2017

Bladder cancer incidence rates have decreased overall in most broad adult age groups in females in the UK since the early 1990s, but have remained stable in some.[1-4] Rates in 0-24s have remained stable, in 25-49s have decreased by 49%, in 50-59s have decreased by 57%, in 60-69s have decreased by 55%, in 70-79s have decreased by 41%, and in 80+s have decreased by 19%.

Bladder Cancer (ICD-10 C67), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2017

Bladder cancer incidence rates have decreased overall in all broad adult age groups in males in the UK since the early 1990s.[1-4] Rates in 0-24s have decreased by 67%, in 25-49s have decreased by 66%, in 50-59s have decreased by 67%, in 60-69s have decreased by 59%, in 70-79s have decreased by 44%, and in 80+s have decreased by 32%.

Bladder Cancer (ICD-10 C67), European Age-Standardised Incidence Rates, By Age, Males, UK, 1993-2017

For bladder cancer, like most cancer types, incidence trends largely reflect changing prevalence of risk factors and improvements in diagnosis and data recording. Recent incidence trends are influenced by risk factor prevalence in years past, and trends by age group reflect risk factor exposure in birth cohorts. Changes in data registration probably also play a part.[5,6]

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  5. Shah A, Rachet B, Mitry E, et al. Survival from bladder cancer in England and Wales up to 2001. Br J Cancer 2008; 99(S1):S86-9 https://www.ncbi.nlm.nih.gov/pubmed/18813272
  6. UK Association of Cancer Registries. Library of Recommendations on Cancer Coding and Classification Policy And Practice: Bladder Cancer. UKACR: Cambridge; 2004

About this data

Data is for UK, 1993-2017, ICD-10 C67.

Last reviewed:

Overall stage at diagnosis

A high proportion (82%) of bladder cancer cases in England and Northern Ireland have stage at diagnosis recorded.[1,2]

Bladder cancer patients with a known stage at diagnosis are most commonly diagnosed at stage I (47-48%). More bladder cancer patients with a known stage are diagnosed at an early stage (73-76% are diagnosed at stage I or II), than a late stage (24-28% are diagnosed at stage III or IV). Between 17% and 20% of bladder cancer patients have metastases at diagnosis (stage IV).[1,2]

The stage distribution for each cancer type will reflect many factors including how the cancer type develops, the way symptoms appear, public awareness of symptoms, how quickly a person goes to see their doctor and how quickly the cancer is recognised and diagnosed by a doctor. It might also relate to whether a national screening programme that can detect early stage disease exists for that cancer type, along with the extent of uptake of that programme.

A cancer type associated with a large proportion of early stage diagnoses could be one that is more likely to be symptomatic at an earlier stage of development, with recognisable symptoms rather than more generic ones.

Bladder Cancer (C67), Proportion of Cases Diagnosed at Each Stage, All Ages, England 2014 and Northern Ireland 2012-2014

Data should not be compared between countries due to differences in time periods and possible differences in recording of stage at diagnosis.

References

  1. National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCIN; 2016
  2. Northern Ireland Cancer Registry, Queens University Belfast, Incidence by stage 2010-2014. Belfast: NICR; 2016 

About this data

Data is for: England 2014, Northern Ireland 2010-2014, ICD-10 C67

Data is not comparable between countries due to differences in time periods and possible differences in how countries record stage at diagnosis.

Last reviewed:

Bladder cancer incidence rates are projected to fall by 34% in the UK between 2014 and 2035, to 13 cases per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, bladder cancer European age-standardised (AS) Open a glossary item incidence rates in the UK are projected to fall by 38% between 2014 and 2035, to 21 cases per 100,000 by 2035.[1] For females, rates are projected to fall by 31% between 2014 and 2035, to 7 cases per 100,000 by 2035.[1]

Bladder cancer (C67), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

 

It is projected that 10,386 cases of bladder cancer (7,531 in males, 2,855 in females) will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C67

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as "increase" or "decrease" if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is evidence for an association between bladder cancer incidence and deprivation for both males and females in England.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item  incidence rates are 27% higher for males living in the most deprived areas compared with the least deprived, and 43% higher for females.[1]

Bladder Cancer (C67), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

The estimated deprivation gradient in bladder cancer incidence between people living in the most and least deprived areas in England has not changed in the period 1996-2010.[1] It has been estimated that there would have been around 730 fewer cancer cases each year in England during 2006-2010 if all people experienced the same incidence rates as the least deprived.[1

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for UK, 2006-2010, ICD-10 C67

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report

Last reviewed:

Age-standardised rates for White males with bladder cancer range from 19.9 to 20.5 per 100,000. Rates for Asian males are significantly lower, ranging from 6.5 to 10.1 per 100,000 and the rates for Black males are also significantly lower, ranging from 5.6 to 9.6 per 100,000. For females there is a similar pattern - the age-standardised rates for White females range from 5.7 to 6.0 per 100,000, and rates for Asian and Black females are also significantly lower ranging from 1.3 to 2.7 per 100,000 and 1.6 to 3.7 per 100,000 respectively.[1]

Ranges are given because of the analysis methodology used to account for missing and unknown data. For bladder cancer, 42,339 cases were identified; 14% had no known ethnicity.

References

  1. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.

About this data

Data is for England, 2002-2006, ICD-10 C67.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs